Use of estrogen agonists / antagonists for the treatment of sexual dysfunction

作者: David Duane Pfizer Global R. D. Thompson , Andrew George Pfizer Global R. D. Lee , Wesley Warren Pfizer Global R. D. Day

DOI:

关键词:

摘要: This invention relates to the use of estrogen agonists / antagonists for manufacture medicaments treatment conditions that are responsive elevation testosterone levels in body. The compositions comprised an agonist antagonist and a pharmaceutically acceptable vehicle, carrier or diluent. These effective treating male subject sexual dysfunction timidity female subjects including post-menopausal women increasing libido women. In case dysfunction, may also include compound which is elevator cyclic guanosine 3',5'-monophosphate (cGMP). Additionally, other whose etiology result deficiency can be ameliorated by within Uses according such as increase uses while substantially reducing concomitant liability adverse effects associated with administration.

参考文章(3)
J Geisler, H Haarstad, S Gundersen, N Raabe, S Kvinnsland, P E Lønning, Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancer. Journal of Endocrinology. ,vol. 146, pp. 359- 363 ,(1995) , 10.1677/JOE.0.1460359
Rosemary Basson, Using a Different Model for Female Sexual Response to Address Women's Problematic Low Sexual Desire Journal of Sex & Marital Therapy. ,vol. 27, pp. 395- 403 ,(2001) , 10.1080/713846827